scholarly journals Circulating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future Perspectives

Cancers ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 367 ◽  
Author(s):  
Vanathi Perumal ◽  
Tammy Corica ◽  
Arun Dharmarajan ◽  
Zhonghua Sun ◽  
Satvinder Dhaliwal ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Primary Tumour ◽  
Personalised Medicine ◽  
Venous Blood ◽  
Tumour Cells ◽  
Treatment Modalities ◽  
Circulating Tumour Cells ◽  
Cancer Management

Head and neck cancer is the seventh most common cancer in Australia and globally. Despite the current improved treatment modalities, there is still up to 50–60% local regional recurrence and or distant metastasis. High-resolution medical imaging technologies such as PET/CT and MRI do not currently detect the early spread of tumour cells, thus limiting the potential for effective minimal residual detection and early diagnosis. Circulating tumour cells (CTCs) are a rare subset of cells that escape from the primary tumour and enter into the bloodstream to form metastatic deposits or even re-establish themselves in the primary site of the cancer. These cells are more aggressive and accumulate gene alterations by somatic mutations that are the same or even greater than the primary tumour because of additional features acquired in the circulation. The potential application of CTC in clinical use is to acquire a liquid biopsy, by taking a reliable minimally invasive venous blood sample, for cell genotyping during radiotherapy treatment to monitor the decline in CTC detectability, and mutational changes in response to radiation resistance and radiation sensitivity. Currently, very little has been published on radiation therapy, CTC, and circulating cancer stem cells (CCSCs). The prognostic value of CTC in cancer management and personalised medicine for head and neck cancer radiotherapy patients requires a deeper understanding at the cellular level, along with other advanced technologies. With this goal, this review summarises the current research of head and neck cancer CTC, CCSC and the molecular targets for personalised radiotherapy response.

scholarly journals Radiotherapy in head and neck cancer management: United Kingdom National Multidisciplinary Guidelines

2016 ◽  
Vol 130 (S2) ◽  
pp. S66-S67 ◽  
Author(s):  
C Nutting
Keyword(s):  
Head And Neck Cancer ◽  
United Kingdom ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Treatment Modalities ◽  
Current Role ◽  
Cancer Management ◽  
Recent Advances ◽  
The Uk

AbstractThis is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. Radiotherapy is one of the key treatment modalities used in head and neck cancer management. This paper summarises the current role and some of the recent advances in radiotherapy in head and neck cancer management.

scholarly journals Impact of label-free technologies in head and neck cancer circulating tumour cells

Oncotarget ◽  
2016 ◽  
Vol 7 (44) ◽  
pp. 71223-71234 ◽  
Author(s):  
Arutha Kulasinghe ◽  
Liz Kenny ◽  
Chris Perry ◽  
Jean-Paul Thiery ◽  
Lidija Jovanovic ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Label Free

scholarly journals Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment

2021 ◽  
Vol 11 (5) ◽  
pp. 393
Author(s):  
Francesca De Felice ◽  
Daniela Musio ◽  
Vincenzo Tombolini
Keyword(s):  
Clinical Trials ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Therapeutic Strategies ◽  
Check Point ◽  
Clinical Tool ◽  
Cancer Management ◽  
Check Point Inhibitors

In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research.

scholarly journals Outcomes of head and neck cancer management from two cancer centres in Southern and Northern Europe during the first wave of COVID-19

2021 ◽  
pp. 030089162110079
Author(s):  
Marta Tagliabue ◽  
Beth Russell ◽  
Charlotte Moss ◽  
Rita De Berardinis ◽  
Francesco Chu ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Ace Inhibitors ◽  
Northern Europe ◽  
Nasopharyngeal Swab ◽  
Cancer Management ◽  
The United Kingdom ◽  
Tertiary Hospitals ◽  
Using Data

Objective: To describe the approach and outcomes from two cancer centres in Southern and Northern Europe during the first wave of coronavirus disease 2019 (COVID-19) of patients with head and neck cancer (HNC). Methods: Data collection was performed on a retrospective cohort of patients surgically treated for primary HNC between March and May 2020, using data from two tertiary hospitals: the European Institute of Oncology (Milan) and Guy’s & St Thomas’ NHS Foundation Trust (London). Results: We included 77 patients with HNC. More patients with COVID-19 were taking angiotensin-converting enzyme (ACE) inhibitors and had Clavien-Dindo Classification grade I compared to negative patients, respectively (60% vs 22% [ p = 0.058] and 40% vs 8% [ p = 0.025]). Multivariate logistic regression analyses confirmed our data ( p = 0.05 and 0.03, respectively). Sex and age were statistically significantly different ( p = 0.05 and <0.001 respectively), showing more male patients (75% vs 53.66%, respectively) and more elderly patients in Italy than in the United Kingdom (patients aged >63 years: 69.44% vs 29.27%). Conclusions: This study presents a large cohort of patients with HNC with nasopharyngeal swab during the first peak of the COVID-19 pandemic in Europe. Patients with HNC with COVID-19 appeared more likely to develop postsurgical complications and to be taking ACE inhibitors. The preventive measures adopted guaranteed the continuation of therapeutic surgical intervention.

Pain in head and neck cancer: management and challenges during recovery

2021 ◽  
Vol 62 (2) ◽  
Author(s):  
Ankita KAR ◽  
Nirmalendu SAHA ◽  
Asheem RAMIZ ◽  
Udayan BHAUMIK ◽  
Satish C
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cancer Management

scholarly journals Medical Gas Plasma Treatment in Head and Neck Cancer—Challenges and Opportunities

2020 ◽  
Vol 10 (6) ◽  
pp. 1944
Author(s):  
Julia Berner ◽  
Christian Seebauer ◽  
Sanjeev Kumar Sagwal ◽  
Lars Boeckmann ◽  
Steffen Emmert ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Plasma Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Treatment Modalities ◽  
Surgical Approaches ◽  
Novel Treatment ◽  
Gas Plasma ◽  
Medical Gas ◽  
Physical Plasma

Despite progress in oncotherapy, cancer is still among the deadliest diseases in the Western world, emphasizing the demand for novel treatment avenues. Cold physical plasma has shown antitumor activity in experimental models of, e.g., glioblastoma, colorectal cancer, breast carcinoma, osteosarcoma, bladder cancer, and melanoma in vitro and in vivo. In addition, clinical case reports have demonstrated that physical plasma reduces the microbial contamination of severely infected tumor wounds and ulcerations, as is often seen with head and neck cancer patients. These antimicrobial and antitumor killing properties make physical plasma a promising tool for the treatment of head and neck cancer. Moreover, this type of cancer is easily accessible from the outside, facilitating the possibility of several rounds of topical gas plasma treatment of the same patient. Gas plasma treatment of head and neck cancer induces diverse effects via the deposition of a plethora of reactive oxygen and nitrogen species that mediate redox-biochemical processes, and ultimately, selective cancer cell death. The main advantage of medical gas plasma treatment in oncology is the lack of adverse events and significant side effects compared to other treatment modalities, such as surgical approaches, chemotherapeutics, and radiotherapy, making plasma treatment an attractive strategy for the adjuvant and palliative treatment of head and neck cancer. This review outlines the state of the art and progress in investigating physical plasma as a novel treatment modality in the therapy of head and neck squamous cell carcinoma.

Sign in / Sign up

Export Citation Format

Share Document